Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

4-Methylumbelliferone improves the thermogenic capacity of brown adipose tissue.

Grandoch M, Flögel U, Virtue S, Maier JK, Jelenik T, Kohlmorgen C, Feldmann K, Ostendorf Y, Castañeda TR, Zhou Z, Yamaguchi Y, Nascimento EBM, Sunkari VG, Goy C, Kinzig M, Sörgel F, Bollyky PL, Schrauwen P, Al-Hasani H, Roden M, Keipert S, Vidal-Puig A, Jastroch M, Haendeler J, Fischer JW.

Nat Metab. 2019 May;1(5):546-559. doi: 10.1038/s42255-019-0055-6. Epub 2019 Apr 22.

PMID:
31602424
2.

In Vitro Recovery of Sufentanil, Midazolam, Propofol, and Methylprednisolone in Pediatric Cardiopulmonary Bypass Systems.

van Saet A, Zeilmaker-Roest GA, van Hoeven MPJ, Koch BCP, van Rosmalen J, Kinzig M, Sörgel F, Wildschut ED, Stolker RJ, Tibboel D, Bogers AJJC.

J Cardiothorac Vasc Anesth. 2019 Aug 29. pii: S1053-0770(19)30896-1. doi: 10.1053/j.jvca.2019.08.029. [Epub ahead of print]

PMID:
31561985
3.

Influence of Sustained Low-Efficiency Dialysis (SLED) treatment on Isavuconazole plasma levels in critically ill patients.

Lahmer T, Batres Baires G, Heilmaier M, Schmid RM, Sörgel F, Kinzig M, Huber W, Mayr U, Rasch S.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01162-19. doi: 10.1128/AAC.01162-19. [Epub ahead of print]

PMID:
31427296
4.

A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Pharm Biomed Anal. 2019 Oct 25;175:112754. doi: 10.1016/j.jpba.2019.07.002. Epub 2019 Jul 3.

PMID:
31336285
5.

Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121718. doi: 10.1016/j.jchromb.2019.121718. Epub 2019 Jul 16.

PMID:
31330406
6.

A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.

Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, Kinzig M, Sörgel F, Stoffel MS, Fuhr U.

Clin Pharmacol Ther. 2019 Jun 27. doi: 10.1002/cpt.1564. [Epub ahead of print]

PMID:
31247117
7.

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jun 18;11(6). pii: E286. doi: 10.3390/pharmaceutics11060286.

8.

The contamination of valsartan and other sartans, part 1: New findings.

Sörgel F, Kinzig M, Abdel-Tawab M, Bidmon C, Schreiber A, Ermel S, Wohlfart J, Besa A, Scherf-Clavel O, Holzgrabe U.

J Pharm Biomed Anal. 2019 Aug 5;172:395-405. doi: 10.1016/j.jpba.2019.05.022. Epub 2019 May 11.

PMID:
31122801
9.

The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.

Scherf-Clavel O, Kinzig M, Besa A, Schreiber A, Bidmon C, Abdel-Tawab M, Wohlfart J, Sörgel F, Holzgrabe U.

J Pharm Biomed Anal. 2019 Aug 5;172:278-284. doi: 10.1016/j.jpba.2019.04.035. Epub 2019 Apr 16.

PMID:
31078064
10.

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.

Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.

Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.

PMID:
30076955
11.

Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;102(3-4):133-137. doi: 10.1159/000489999. Epub 2018 Jul 6.

PMID:
29982257
12.

Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?

Gazzaz M, Kinzig M, Schaeffeler E, Jübner M, Hsin CH, Li X, Taubert M, Trueck C, Iltgen-Breburda J, Kraus D, Queckenberg C, Stoffel M, Schwab M, Sörgel F, Fuhr U.

Clin Pharmacol Ther. 2018 Dec;104(6):1249-1259. doi: 10.1002/cpt.1083. Epub 2018 May 10.

PMID:
29633238
13.

Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091. Epub 2017 Sep 21.

14.

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.

15.

Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens.

Lübbert C, Baars C, Dayakar A, Lippmann N, Rodloff AC, Kinzig M, Sörgel F.

Infection. 2017 Aug;45(4):479-491. doi: 10.1007/s15010-017-1007-2. Epub 2017 Apr 26.

PMID:
28444620
16.

[Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].

Sörgel F, Höhl R, Glaser R, Stelzer C, Munz M, Vormittag M, Kinzig M, Bulitta J, Landersdorfer C, Junger A, Christ M, Wilhelm M, Holzgrabe U.

Med Klin Intensivmed Notfmed. 2017 Feb;112(1):11-23. doi: 10.1007/s00063-016-0185-5. Epub 2016 Oct 24. Review. German.

PMID:
27778050
17.

Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples.

Sigaroudi A, Stelzer C, Braun T, Frechen S, Hüttner S, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2016;98(1-2):70-2. doi: 10.1159/000445720. Epub 2016 Apr 23.

PMID:
27104875
18.

Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.

Sörgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M.

BioDrugs. 2015 Apr;29(2):123-31. doi: 10.1007/s40259-015-0124-7.

19.

Challenges of surveying wastewater drug loads of small populations and generalizable aspects on optimizing monitoring design.

Ort C, Eppler JM, Scheidegger A, Rieckermann J, Kinzig M, Sörgel F.

Addiction. 2014 Mar;109(3):472-81. doi: 10.1111/add.12405. Epub 2013 Dec 10.

PMID:
24325468
20.

Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA.

Antimicrob Agents Chemother. 2014;58(3):1320-6. doi: 10.1128/AAC.02090-12. Epub 2013 Dec 9.

21.

Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M.

Antimicrob Agents Chemother. 2013 Apr;57(4):1736-42. doi: 10.1128/AAC.02011-12. Epub 2013 Jan 28.

22.

The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.

Goessens WH, Mouton JW, Ten Kate MT, Sörgel F, Kinzig M, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2013 Jan;57(1):643-6. doi: 10.1128/AAC.01154-12. Epub 2012 Nov 5.

23.

Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F.

Antimicrob Agents Chemother. 2012 Nov;56(11):5715-23. doi: 10.1128/AAC.00937-12. Epub 2012 Aug 20.

24.

Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M.

Antimicrob Agents Chemother. 2012 Feb;56(2):1059-64. doi: 10.1128/AAC.05490-11. Epub 2011 Nov 14.

25.

Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination.

Bulitta JB, Kinzig M, Naber CK, Wagenlehner FM, Sauber C, Landersdorfer CB, Sörgel F, Naber KG.

Chemotherapy. 2011;57(5):402-16. doi: 10.1159/000329520. Epub 2011 Oct 18.

PMID:
22024700
26.

An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study.

Elsinghorst PW, Kinzig M, Rodamer M, Holzgrabe U, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1686-96. doi: 10.1016/j.jchromb.2011.04.012. Epub 2011 Apr 20.

PMID:
21536505
27.

Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.

Bulitta JB, Kinzig M, Landersdorfer CB, Holzgrabe U, Stephan U, Sörgel F.

Antimicrob Agents Chemother. 2011 Jun;55(6):2927-36. doi: 10.1128/AAC.01484-10. Epub 2011 Mar 14.

28.

Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.

Rodamer M, Elsinghorst PW, Kinzig M, Gütschow M, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 1;879(11-12):695-706. doi: 10.1016/j.jchromb.2011.02.006. Epub 2011 Feb 28.

PMID:
21367676
29.

Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.

Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1606-10. doi: 10.1128/AAC.01330-10. Epub 2011 Feb 7.

30.

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt F, Lindauer A, Kinzig M, Strumberg D, Scheulen ME, Mross K, Fischer R, Moritz B, Sörgel F, Jaehde U.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):88-90. No abstract available.

PMID:
21176741
31.

Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis.

Nagy N, Freudenberger T, Melchior-Becker A, Röck K, Ter Braak M, Jastrow H, Kinzig M, Lucke S, Suvorava T, Kojda G, Weber AA, Sörgel F, Levkau B, Ergün S, Fischer JW.

Circulation. 2010 Nov 30;122(22):2313-22. doi: 10.1161/CIRCULATIONAHA.110.972653. Epub 2010 Nov 15.

PMID:
21098434
32.

Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NH.

Br J Clin Pharmacol. 2010 Nov;70(5):682-93. doi: 10.1111/j.1365-2125.2010.03750.x.

33.

Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.

Lengerke C, Haap M, Mayer F, Kanz L, Kinzig M, Schumacher U, Sörgel F, Riessen R.

Antimicrob Agents Chemother. 2011 Jan;55(1):449-50. doi: 10.1128/AAC.00635-10. Epub 2010 Oct 11. No abstract available.

34.

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U.

Clin Pharmacol Ther. 2010 May;87(5):601-8. doi: 10.1038/clpt.2010.20. Epub 2010 Apr 7. Erratum in: Clin Pharmacol Ther. 2010 Oct;88(4):566.

PMID:
20376000
35.

Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.

Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sörgel F.

Br J Clin Pharmacol. 2010 Feb;69(2):167-78. doi: 10.1111/j.1365-2125.2009.03564.x.

36.

Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.

Bulitta JB, Landersdorfer CB, Hüttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sörgel F.

Antimicrob Agents Chemother. 2010 Mar;54(3):1275-82. doi: 10.1128/AAC.00936-09. Epub 2010 Jan 11.

37.

The role of silver nitrate as additive in non-aqueous capillary electrophoresis.

Hashem H, Kinzig M, Jira T.

Pharmazie. 2009 Oct;64(10):633-7.

PMID:
19947163
38.

Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.

Bulitta JB, Duffull SB, Landersdorfer CB, Kinzig M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):130-41. doi: 10.1016/j.diagmicrobio.2009.06.018.

PMID:
19748423
39.

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4718-25. doi: 10.1128/AAC.00802-09. Epub 2009 Aug 17.

40.

Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F.

Antimicrob Agents Chemother. 2009 Sep;53(9):3902-7. doi: 10.1128/AAC.01200-08. Epub 2009 Jun 29.

41.

New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.

Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F.

Antimicrob Agents Chemother. 2009 Aug;53(8):3462-71. doi: 10.1128/AAC.00054-09. Epub 2009 Jun 15.

42.

Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration.

Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M.

Int J Clin Pharmacol Ther. 2009 Jun;47(6):391-401.

PMID:
19473601
43.

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.

Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M.

BMC Clin Pharmacol. 2009 May 22;9:10. doi: 10.1186/1472-6904-9-10.

44.

Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.

Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL.

J Clin Pharmacol. 2009 Jul;49(7):816-23. doi: 10.1177/0091270009337133. Epub 2009 May 14.

PMID:
19443680
45.

Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.

Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, Sörgel F, Rodamer M, Fuhr U.

Antimicrob Agents Chemother. 2009 Jul;53(7):2892-901. doi: 10.1128/AAC.01193-08. Epub 2009 May 4.

46.

Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation.

Landersdorfer CB, Kinzig M, Bulitta JB, Hennig FF, Holzgrabe U, Sörgel F, Gusinde J.

Antimicrob Agents Chemother. 2009 Jun;53(6):2569-78. doi: 10.1128/AAC.01119-08. Epub 2009 Mar 23.

47.

Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sörgel F.

Clin Pharmacokinet. 2009;48(2):89-124. doi: 10.2165/0003088-200948020-00002. Review.

PMID:
19271782
48.

Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.

Landersdorfer CB, Kinzig M, Hennig FF, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F, Gusinde J.

Antimicrob Agents Chemother. 2009 May;53(5):2074-81. doi: 10.1128/AAC.01056-08. Epub 2009 Feb 17.

49.

In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.

Doroshyenko O, Fuhr U, Kunz D, Frank D, Kinzig M, Jetter A, Reith Y, Lazar A, Taubert D, Kirchheiner J, Baum M, Eisenbrand G, Berger FI, Bertow D, Berkessel A, Sörgel F, Schömig E, Tomalik-Scharte D.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):433-43. doi: 10.1158/1055-9965.EPI-08-0832. Epub 2009 Feb 3.

50.

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations.

Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M.

Pharmacology. 2009;83(2):122-30. doi: 10.1159/000189027. Epub 2008 Dec 22.

Supplemental Content

Loading ...
Support Center